Teva Pharmaceutical Industries Return on Tangible Equity 2010-2024 | TEVA
Current and historical return on tangible equity values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Teva Pharmaceutical Industries Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.45B |
$-14.78B |
3.08% |
| 2024-03-31 |
$-0.48B |
$-14.52B |
3.24% |
| 2023-12-31 |
$-0.56B |
$-14.44B |
3.75% |
| 2023-09-30 |
$-2.33B |
$-14.90B |
15.38% |
| 2023-06-30 |
$-2.35B |
$-15.15B |
15.44% |
| 2023-03-31 |
$-1.71B |
$-15.15B |
11.13% |
| 2022-12-31 |
$-2.45B |
$-15.31B |
15.49% |
| 2022-09-30 |
$-1.29B |
$-15.31B |
8.05% |
| 2022-06-30 |
$-1.05B |
$-15.71B |
6.45% |
| 2022-03-31 |
$-0.62B |
$-16.84B |
3.68% |
| 2021-12-31 |
$0.42B |
$-16.26B |
-2.46% |
| 2021-09-30 |
$0.73B |
$-16.56B |
-4.15% |
| 2021-06-30 |
$-3.92B |
$-17.23B |
21.62% |
| 2021-03-31 |
$-3.98B |
$-17.77B |
21.26% |
| 2020-12-31 |
$-3.99B |
$-18.49B |
20.64% |
| 2020-09-30 |
$-4.03B |
$-18.94B |
20.19% |
| 2020-06-30 |
$0.00B |
$-19.73B |
-0.02% |
| 2020-03-31 |
$-0.83B |
$-20.16B |
3.89% |
| 2019-12-31 |
$-1.00B |
$-21.02B |
4.60% |
| 2019-09-30 |
$-4.05B |
$-21.61B |
18.19% |
| 2019-06-30 |
$-4.01B |
$-22.10B |
17.57% |
| 2019-03-31 |
$-3.56B |
$-22.19B |
15.21% |
| 2018-12-31 |
$-2.40B |
$-23.13B |
9.88% |
| 2018-09-30 |
$-11.06B |
$-23.80B |
43.68% |
| 2018-06-30 |
$-10.26B |
$-24.49B |
38.18% |
| 2018-03-31 |
$-16.05B |
$-25.68B |
55.80% |
| 2017-12-31 |
$-16.53B |
$-27.31B |
55.15% |
| 2017-09-30 |
$-5.96B |
$-29.98B |
19.32% |
| 2017-06-30 |
$-6.15B |
$-32.09B |
19.46% |
| 2017-03-31 |
$0.08B |
$-30.47B |
-0.34% |
| 2016-12-31 |
$0.07B |
$-30.90B |
-0.45% |
| 2016-09-30 |
$1.59B |
$-32.83B |
-24.41% |
| 2016-06-30 |
$1.35B |
$1.78B |
222.11% |
| 2016-03-31 |
$1.70B |
$1.75B |
-181.40% |
| 2015-12-31 |
$1.57B |
$3.23B |
-104.94% |
| 2015-09-30 |
$1.78B |
$-4.33B |
-72.54% |
| 2015-06-30 |
$2.55B |
$-4.39B |
-158.26% |
| 2015-03-31 |
$2.76B |
$-0.50B |
-317.44% |
| 2014-12-31 |
$3.06B |
$-0.57B |
-232.72% |
| 2014-09-30 |
$2.75B |
$-0.99B |
-146.42% |
| 2014-06-30 |
$2.58B |
$-1.42B |
-102.87% |
| 2014-03-31 |
$1.38B |
$-2.28B |
-43.68% |
| 2013-12-31 |
$1.27B |
$-2.82B |
-37.46% |
| 2013-09-30 |
$1.21B |
$-3.52B |
-33.44% |
| 2013-06-30 |
$0.42B |
$-4.04B |
-11.30% |
| 2013-03-31 |
$1.73B |
$-3.16B |
-45.51% |
| 2012-12-31 |
$1.96B |
$-3.73B |
-45.95% |
| 2012-09-30 |
$2.15B |
$-3.89B |
-43.81% |
| 2012-06-30 |
$3.14B |
$-4.45B |
-84.81% |
| 2012-03-31 |
$2.86B |
$-5.01B |
-132.38% |
| 2011-12-31 |
$2.76B |
$-6.27B |
-460.03% |
| 2011-09-30 |
$3.02B |
$0.90B |
247.56% |
| 2011-06-30 |
$3.16B |
$1.74B |
298.07% |
| 2011-03-31 |
$3.38B |
$1.22B |
225.38% |
| 2010-12-31 |
$3.33B |
$1.02B |
166.05% |
| 2010-09-30 |
$2.94B |
$0.26B |
123.27% |
| 2010-06-30 |
$2.54B |
$3.50B |
87.33% |
| 2010-03-31 |
$2.26B |
$3.25B |
96.18% |
| 2009-12-31 |
$2.00B |
$2.53B |
142.27% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.902B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
